Barclays Maintains Overweight on CME Gr, Lowers Price Target to $244
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Jeremy Campbell has maintained an Overweight rating on CME Group (NASDAQ:CME) but lowered the price target from $247 to $244.
October 26, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays has maintained an Overweight rating on CME Group but lowered the price target from $247 to $244.
The news is directly about CME Group. Barclays' decision to maintain an Overweight rating indicates a positive outlook for the company. However, the lowering of the price target could suggest a slightly less optimistic view on the company's future stock price. This could have a neutral impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100